CV Sciences (CVSI) Other Non-Current Liabilities (2015 - 2024)

CV Sciences (CVSI) posted Other Non-Current Liabilities of $38000.0 for Q3 2024, down 60.0% sequentially from $95000.0 in Q2 2024.

CV Sciences (CVSI) Other Non-Current Liabilities (2015 - 2024) Analysis & Trends

CV Sciences has reported Other Non-Current Liabilities for 6 years, with the latest figure at $38000.0 in Q3 2024.

Quarterly Other Non-Current Liabilities changed N/A year-over-year to $38000.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $38000.0 (changed N/A YoY) and the FY2023 annual result came in at $105000.0, changed N/A from the prior year.
Other Non-Current Liabilities fell to $38000.0 in Q3 2024 per CVSI's latest filing, from $95000.0 in the prior quarter.
Over five years, Other Non-Current Liabilities peaked at $171000.0 in Q1 2020 and troughed at $38000.0 in Q3 2024.
A 3-year average of $102400.0 and a median of $103000.0 in 2024 frame the typical range for Other Non-Current Liabilities.
The widest YoY moves for Other Non-Current Liabilities: up 60.87% in 2020, down 60.87% in 2020.
Over 3 years, Other Non-Current Liabilities stood at $171000.0 in 2020, then slumped by 38.6% to $105000.0 in 2023, then slumped by 63.81% to $38000.0 in 2024.
According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $38000.0, $95000.0, and $103000.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-
10	CV Sciences	4.10 Mn	3.84 Mn	1.45 Mn

Download Data